150: Why Tirzepatide Works Better Than GLP-1 Alone

Bikman is loath to see anyone go to a higher dose than they need to. He has long maintained that the lowest effective dose is best. This aligns with his view that the drug is not a permanent fix but a window to retrain eating behavior. By minimizing escalation, patients preserve tolerability, reduce cost and potential unknown long-term risks, and maximize the period during which they can consciously reshape their diet. He contrasts this with a mindset that might chase ever-stronger doses thinking more drug equals more magic, which he explicitly refutes—the drug only works by reducing intake and cravings. Keeping the dose low forces the patient to also rely on behavioral change, which is the ultimate goal.

Bikman argues that the drug's best use case is as a crutch to help someone who has lost control of carbohydrate cravings regain that control. The published evidence shows the drug heavily pulls down cravings for sweets and starches. During the months or years on the medication, a person can experience what satiety feels like on a lower carbohydrate intake, normalize fasting insulin, and reshape the eating behaviors that drove the metabolic dysfunction. He emphasizes that the food you eat is either the culprit or the cure, and the drug makes it easier to choose the cure. Without this intentional habit shift, the drug becomes a permanent appetite override, and upon discontinuation, the underlying addiction returns unchanged. He frames this as moving from addiction to moderation, learning to walk past an irresistible temptation, and rewire the brain's reward association with food.